Compare FTHM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | FEMY |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 37.2M |
| IPO Year | 2020 | 2021 |
| Metric | FTHM | FEMY |
|---|---|---|
| Price | $0.96 | $0.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $6.83 |
| AVG Volume (30 Days) | 230.6K | ★ 1.1M |
| Earning Date | 03-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $421,612,000.00 | $2,061,502.00 |
| Revenue This Year | $30.07 | $64.02 |
| Revenue Next Year | $14.66 | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 32.78 | ★ 63.53 |
| 52 Week Low | $0.65 | $0.31 |
| 52 Week High | $3.37 | $1.80 |
| Indicator | FTHM | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 32.72 |
| Support Level | $1.25 | $0.53 |
| Resistance Level | $1.30 | $0.56 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 3.85 | 2.94 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.